Agrylin – Platelet Reduction with Agrylin

Anagrelide HCI is the chemical name for Agrylin. It is a drug used in the treatment of essential thrombocythemia. Agrylin reduces the number of platelets to help prevent blood from clotting inside the body.

Patients with essential thrombocythemia suffer from a blood disorder where the bone marrow generates too many platelets. The escalated platelet count may cause circulatory problems, including undue clotting and bleeding. Agrylin is used to inhibit the production of the platelets. There are cells in the body called megakaryocyte cells. As these cells mature they create platelets. The Anagrelide HCI in Agrylin prevents the maturation of the megakaryocyte cells through inhibiting a specific enzyme necessary for the maturation process.

Agrylin, like all drugs, may cause a variety of side effects. More common side effects may include headache, mild nausea, muscle or joint pain, insomnia, constipation or diarrhoea, rash, dizziness, sore throat, congestion or runny nose, numbness or tingling in the extremities. The more serious side effects, which require immediate medical attention, of Agrylin include convulsions, blood in the urine or stool, swelling, chest pains, sudden numbness, confusion, shortness of breath, irregular heart rate, fever, severe pain in the upper stomach, feeling faint. As with all medication, if a serious allergic reaction, like trouble breathing, swelling in the tongue or throat, see a doctor immediately. In addition, drugs with Anagrelide HCI should not be taken by patients with liver or kidney disease. If prescribed this medicine, be aware of the potential adverse interaction between the drug and grapefruit products and discuss the potential effects with a doctor. As with most drugs, a prescription from a licensed physician is required to obtain this medication from a Canadian pharmacy, including online pharmacies.